Revision of the Synthesis and Pharmacological Activity of a Reported Translation Inhibitor.
Fiche publication
Date publication
juin 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent
Tous les auteurs :
Basmadjian C, Malka-Mahieu H, Desaubry L
Lien Pubmed
Résumé
4EGI-1 is the prototype of a novel class of anticancer agents targeting translation. Patented drug-like analogue 1 was synthesized and examined for inhibition of translation and cytotoxicity in cancer cells. Unexpectedly, 1 was found inactive in both assays.
Référence
Anticancer Agents Med Chem. 2015 Jun 1.